# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹1,000 Cr** Q4 (+32.8% YoY / +6.5% QoQ) · **₹3,510.5 Cr** FY26 (+23.6% INR / +18.2% USD) * **Adjusted EBITDA:** **₹188.9 Cr** Q4 (+23.2% YoY) · **₹679.3 Cr** FY26 (+20.8% YoY) * **PAT:** **₹797 Mn** Q4 · **₹4,011 Mn** FY26 (-1.4% YoY) · **₹4,583 Mn** FY26 Adjusted (+12.7% YoY) * **Cash Flow:** **₹650.8 Cr** OCF (+47% YoY) · **₹606.5 Cr** FCF (+47% YoY) * **DSO:** **63 Days** FY26 (vs. 72 Days FY25) ## B. Revenue Growth * **Historic Milestone:** Achieved record quarterly and annual top-line performance, crossing the ₹1,000 Cr quarterly threshold for the first time. * **Client Concentration & Expansion:** Robust growth from the top 20 customers, reaching **₹2,520 Cr**, driven by recurring engagements and a diversified service portfolio. * **Organic Momentum:** Delivered double-digit organic growth YoY in constant currency, supported by a healthy mix of new and existing business. * **Revenue Recognition Shift:** A significant **$10 million win** from Q3 will be fully deferred to FY27, a result of the company's shift toward outcome-based pricing models. ## C. Margins & Profitability * **Productivity Gains:** Revenue per employee surged to **USD 75,000**, up from USD 56,000 three years ago, credited to AI integration and managed-outcome contracts. * **Accounting & One-offs:** Transitioned to cash flow hedge accounting; reported net profit was weighed down by a legal provision, lower interest yields, and acquisition-related amortization. * **Adjusted Earnings:** Normalizing for non-operational expenses and retroactive hedge accounting reveals a double-digit growth trajectory in bottom-line profitability. ## D. Cash Flow & Liquidity * **Cash Conversion Excellence:** Operating cash flow reached a high ratio of 162% on PAT, bolstered by improved working capital management and higher non-cash expenses. * **Working Capital Efficiency:** Significant reduction in debtor days from historical mid-80s to the low 60s; management targets a steady-state range of **65 to 70 days**. * **Strong Balance Sheet:** Robust free cash flow generation has built a total cash and investment reserve of **₹1,538.5 Cr** to end the fiscal year. --- # 2. Customer & Market Metrics ## A. Key Figures * **Client Concentration:** Serving all 20 of the top global pharma companies * **Active Customer Base:** **91** Total (+25% YoY) · **53** >$1M Revenue (+30% YoY) * **Geography Mix:** **71.6%** North America (+200 bps) · **25.5%** Europe · **2.9%** RoW * **Segment Growth (YoY):** **17%** Enterprise Commercial (ex-BioPharm) · **16%** EMS · **15%** BioPharm (Q4 sequential) ## B. Client Cohorts & Momentum * **Strategic Account Deepening:** Maintained 100% penetration of the top 20 global pharma companies, with a significant "Tectonic" win in Germany set to elevate the largest client to a **$50 million-plus** account in FY27. * **Rapid Mid-Tier Scaling:** The "land and expand" strategy is yielding results as the cohort outside the top 20 is growing faster on a percentage basis, driven by new relationships quickly reaching the **$5 million ACV** threshold. * **Pipeline Diversification:** Entering FY27 with a larger, more balanced sales funnel; recent Q4 momentum included **eight deals** exceeding $1 million ACV, spanning both clinical and commercial segments. ## C. Segment Performance & Market Share * **Disruptive Market Capture:** Actively gaining share from traditional agencies and CROs by absorbing spend pools across clinical operations and regulatory costs, a trend accelerated by GenAI integration. * **Biotech Launch Model:** Emerging as a preferred partner for mid-sized biotech firms, providing end-to-end commercialization that allows for product launches with minimal physical sales forces via omnichannel engagement. * **Next-Gen Operating Models:** Secured **six major wins** in high-tech domains, including "Human-less" Medical Legal Review and Agentic AOR, positioning the firm as a high-value revenue partner rather than a cost-center. ## D. Geography & Retention Strategy * **Regional Expansion:** North American dominance was further bolstered by the U.S.-focused BioPharm acquisition, while European growth is being driven by regional expansions within existing top-tier accounts. * **Platform Conversion:** Management is focused on converting initial pilots into long-term platforms to establish new industry-standard operating models and secure additional **$25 million-plus** relationships. --- # 3. Technology & Innovation ## A. Key Figures * **Revenue per Employee (RPE):** **$75,000** current period (vs. **$67,000** YoY) * **R&D Investment:** **>2%** of total revenues ## B. GenAI & Platforms * **Accelerated Value Delivery:** GenAI-led innovation is compressing delivery timelines, notably reducing strategic brand work cycles from **3 months to 3 days** for a top 20 pharma client. * **High-Value Mandates:** Secured a major contract for a **$1 billion U.S. portfolio** using the Invisage and Tandem platforms for personalized GenAI targeting. * **Platform Scaling:** Active deployment of the **Content Super App** and **Cortex** (knowledge engineering platform) is driving "agentic" workflows that decouple domain expertise from the underlying technology layer. * **Strategic Innovation:** Established a global innovation center for a **$100 billion market cap** entity to accelerate FDA submissions and molecule speed-to-market via GenAI. * **Future Revenue Drivers:** The **Tectonic** transformation model has secured five customers, with meaningful revenue contribution expected in **FY27**. ## C. Product Portfolio * **Disruptive Service Models:** The Agency-of-Record (AOR) replacement model utilizes synthetic KOLs and AI agents to eliminate traditional, high-cost agency processes. * **Specialized AI Applications:** Deploying proprietary **NAEM technology** for medical device clients to automate global pharmacovigilance and adverse event reporting. * **Competitive Moat:** Differentiation is maintained through "human-in-the-loop" workflows and the integration of proprietary data with frontier LLMs, targeting complex problems standard models cannot solve. ## D. Operational Efficiency * **Productivity Gains:** Significant growth in RPE reflects a five-year upward trend from a **$51,000** base, supported by a marginal increase in on-site presence. * **Pricing Evolution:** Shifting toward **outcome-based or output-based pricing** to capture and retain productivity gains that would otherwise be lost under traditional timesheet models. * **Internal Transformation:** The **"Transform AI"** program is reengineering internal processes to further boost employee productivity and capture adjacent market revenue. --- # 4. Strategic Initiatives ## A. Key Figures * **M&A Outflow:** **₹725.3 Cr** for three acquisitions * **Year-End Cash Position:** **₹125.8 Cr** lower than FY25 closing balance * **Proposed Dividend:** **₹2.25** per equity share (+12.5%) * **Workforce:** **5,000+** global colleagues ## B. M&A Integration * **Strategic Expansion:** Completed three acquisitions in **FY26** (BioPharm, Warn, and Cake Communications) to bolster omnichannel data capabilities and European market credibility. * **Synergy Realization:** BioPharm integration finished ahead of schedule; transition service conclusions are expected to drive immediate G&A cost efficiencies in **Q1 FY27**. ## C. Business Model & Positioning * **Value Proposition:** Differentiates as a "strategic operating partner" rather than an IT services firm, leveraging nearly three decades of domain expertise to run complex R&D and commercial models. * **AI-Resilient Pricing:** Utilizes outcome-based commercial models over effort-based billing, protecting margins as AI automation reduces traditional billable hours. * **Market Capture:** Positioning as a specialized tech-led partner to consolidate spend within the R&D and CRO segments. ## D. Capital Allocation * **Balance Sheet Resilience:** Maintained a robust cash position despite significant capital deployment for inorganic growth, with the net cash decrease being substantially lower than the total acquisition spend. * **Shareholder Returns:** Increased the final dividend payout, reflecting confidence in cash flow generation and long-term compounding. ## E. Leadership & Talent * **Domain Depth:** Competitive advantage in GenAI is anchored by a workforce where **one-third** of staff hold specialized medical, regulatory, or technical roles. * **C-Suite Engagement:** Strengthened senior and medical leadership tiers to better manage large-scale transformation mandates and high-level client relationships. --- # 5. Life Sciences Risks ## A. Key Figures * **Legal Provision:** **₹203 Mn** One-time exceptional item for TCPA lawsuit settlement * FX Impact: ₹241 million incremental charge on unexpired forward contracts * **EBITDA:** **₹164.8 Cr** Q4 reported figure (impacted by FX volatility) * **Industry Growth:** **9%** CY2025 pharmaceutical market growth · **5% to 8%** Projected CAGR (2026-2028) ## B. Regulatory & Legal * **Litigation Resolution:** Management has provisioned for a legacy **FY19-20** U.S. class action settlement related to fax outreach; the channel is now inactive with no further anticipated exposures. * **AI Guardrails:** Domain-led tasks remain "human-in-the-loop" as LLMs currently lack the reliability for life sciences, a stance validated by recent **FDA warning letters** regarding AI-generated content. * **Expertise Moat:** Human judgment is deemed critical for the next **3 to 5 years** in high-stakes areas like pharmacovigilance and therapeutic strategy. ## C. Change Management & Macro Volatility * **Adoption Headwinds:** Expansion within large-client cohorts is facing temporary friction from internal change management and the lead time required for clients to transition to new operating models. * **Currency Headwinds:** Reported earnings were pressured by significant exchange rate volatility and INR depreciation against the USD, necessitating a substantial incremental charge. * **Improved Outlook:** Confidence for **FY27** has strengthened as previous uncertainties regarding U.S. regulatory policy and macro volatility have largely stabilized. --- # 6. Guidance & Outlook ## A. Key Figures * **Margin Headwinds:** **150 bps** impact from recent investments * **Contract Win:** **>$10M** ACV multi-year omnichannel deal ## B. FY27 Projections * **Growth Conviction:** Management anticipates robust momentum across Enterprise Commercial and Medical segments, fueled by inorganic depth in Europe and AI-driven innovation. * **Profitability Inflection:** PAT is expected to see a significant upward shift in FY27, supported by stable amortization, the absence of one-off items, and positive interest income from high cash reserves. * **Strategic Continuity:** The FY27 roadmap prioritizes scaling existing FY26 initiatives and talent investments over shifting strategic direction. ## C. Margin Recovery * **Operating Leverage:** EBITDA margins are projected to return to historical highs by H2 FY27 as the business fully absorbs the impact of previous investments. * **Synergy Realization:** Progressive margin expansion is expected throughout the year, driven by post-acquisition synergies in data subscriptions and business operations. * **Reinvestment Strategy:** Management intends to reinvest any margin gains exceeding their target operating range back into the business to sustain long-term growth. ## D. Growth Pipeline * **Revenue Conversion:** A major omnichannel win and a significant Q4 contract in Germany (Tectonic) are positioned to become material revenue drivers in the latter half of FY27. * **AI Commercialization:** Growth is increasingly underpinned by GenAI-led wins transitioning from pilot phases to long-term, hard-dollar commitments. * **Client Expansion:** Future scaling relies on AI-embedded medical operating models and deepening penetration within both Top 20 and mid-tier client cohorts.